Showing results (711-720 of 1,303) with videos related to
Sort By:
Pageof 131
Journal of Gynecologic Oncology|August 29, 2022
Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinomaTamaki Tanaka, Kazuhiro Takehara, Natsumi Yamashita, et al.Journal of Gynecologic Oncology|August 29, 2022
Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamicsIkuo Konishi, Kaoru Abiko, Takuma Hayashi, et al.Journal of Gynecologic Oncology|August 11, 2021
Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysisMasato Yoshihara, Satoshi Tamauchi, Shohei Iyoshi, et al.Journal of Gynecologic Oncology|August 25, 2021
MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomasEnami Kaneko, Naoki Sato, Tae Sugawara, et al.Journal of Gynecologic Oncology|August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional studyBurak Zeybek, Emily Webster, Natalia Pogosian, et al.Journal of Gynecologic Oncology|April 28, 2021
Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitroHemavathi Dhandapani, Abirami Seetharaman, Hascitha Jayakumar, et al.Journal of Gynecologic Oncology|April 23, 2020
Major clinical research advances in gynecologic cancer in 2019Miseon Kim, Dong Hoon Suh, Kyung Hun Lee, et al.Journal of Gynecologic Oncology|November 11, 2022
Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry studySe Ik Kim, Ji Hyun Kim, Cheol Lee, et al.Journal of Gynecologic Oncology|November 11, 2022
Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire surveyMikiko Asai-Sato, Nao Suzuki, Hitomi Sakai, et al.Journal of Gynecologic Oncology|December 12, 2022
Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancerJin Hwa Hong, Hyun Woong Cho, Yung-Taek Ouh, et al.Pageof 131